Chronic liver disease is characterized by liver fibrosis, which may lead to cirrhosis. Conventional serum-based liver function tests do not give information on either the presence or the rate of progress of liver fibrosis. The reference diagnostic test to detect fibrosis is liver biopsy, a procedure subject to various limitations, including risk of patient injury and sampling error. Serum markers have been evaluated for the determination of fibrosis either singly or combined as a panel of markers, however diagnostic accuracy is greatest in studies using a panel together with an algorithm, which generates a predictive score. Serum marker models, especially those targeted at hepatitis C, have multiplied in spectacular fashion over the last five years, with most models regularly achieving a median area under the receiver operating characteristic curve (ROCC) of 0.80 versus liver biopsy. Five years after publication of the first major serum marker model, the first study to document clinical outcomes reported that applying the model to hepatitis C patients improved prediction of decompensated cirrhosis and survival compared to liver biopsy. An obstacle to widespread adoption of serum marker models has been the lack of uniform performance indicators, such as diagnostic odds ratios and likelihood ratios. This review highlights the most well-established noninvasive biomarkers to-date, with a particular emphasis on serum
Introduction
Chronic liver diseases of differing etiologies are among the leading causes of morbidity and mortality worldwide [1-5]. Chronic liver disease progresses through different pathological stages that vary from mild hepatic inflammation without fibrosis to advanced hepatic fibrosis and cirrhosis [6-8]. Assessment of the stage of liver disease is important for diagnosis, treatment, and follow-up both during treatment and after cessation of treatment. A liver biopsy is the oldest and most accurate method used to evaluate liver histology and the progression of chronic liver disease. Furthermore, different histological scoring systems have been developed and modified [9-12]. Liver biopsy -an "imperfect" gold standard Biopsy has been the gold standard in diagnosing and staging liver fibrosis and also has the advantage of assessing other disease aspects as well including inflammation, steatosis and necrosis. However, biopsy is often considered an "imperfect" gold standard since it suffers from intra/inter-observer variability and is associated with several complications including hospitalization in 1-5% of cases and mortality in 0.01-0.1% of cases. [13] [14] In addition, biopsy is subject to sampling error as the 1-2 pieces of 1 cm long tissue only accounts for 1/50,000 of the liver volume.
[15] For example, laparoscopic liver biopsies from the right and left lobes of HCV patients differed by at least one Metavir stage in 33% of cases, [16] and higher sampling variability has been reported for NASH and biliary fibrosis.[17-18] Sampling error even exists for advanced stages of disease as biopsy can lead to under-staging of cirrhosis in up to 20% of patients. [19] Importantly, repeated biopsies to evaluate disease progression or response to treatment are impractical due to the increased risk of complications and poor patient compliance. For all of these reasons, noninvasive strategies that can repeatedly assess liver fibrosis throughout the entire organ are urgently needed to assess disease stage, monitor treatment response, and determine prognosis. Recently many noninvasive markers (NIMs) for assessing liver fibrosis have been developed, and they are frequently used in clinical practice. They have been validated in different studies, and some were found to be highly accurate in the assessment of liver fibrosis compared with liver biopsies [20-23], which have always been used as the standard reference method for evaluating the accuracy of noninvasive methods. Most non-invasive markers of liver fibrosis were developed with the aim of discriminating between 'insignificant", (F0 -F1)by METAVIR and clinically "significant" fibrosis (> F 2 )by • Liver specific • Noninvasive • Easy to perform • Measurable by sensitive, reproducible and fast methodology • Serum levels are independent of alterations in liver, renal or reticuloendothelial function 1. Capacity to reflect one or more of the following processes: -stage of fibrosis; -activity of matrix deposition; -activity of matrix removal. 2. Possibility to follow the progression or regression of fibrosis in natural evolution or under treatment
The accuracy of a test is given as the area under the curve (AUC)of the receiver operator characteristic (ROC).An ideal marker would have an AUC of 1.0 and thus a 100% sensitivity and specificity.The great majority of proposed biochemical markers have an AUC between 0.80-0.85 and have value not for staging the disease, but rather for differentiating insignificant (F0/F1)from significant fibrosis (F2-F4 Metavir).Moreover, the indeterminate results occur mainly in patients who have F1 to F2 disease.Taking into account that the value of a biomarker is validated against the biopsy, which has an accuracy of about 80%. It is improbable that a biomarker has a better performance than liver biopsy for staging fibrosis [25] According to Afdhal and Nune, 2004 none of the available markers fulfill these ideal criteria.None are liver specific, so there may be significant contribution from non-hepatic sources, including bone, joints, skin, and lungs.Levels of these markers are altered by changes in their clearance, metabolism, and excretion.For instance, both the liver (80%)and the kidneys (20%)clear hyaluronan and the removal from circulation is also dependent upon binding to specific receptors by hepatic endothelial cells [26] .Increased hyaluronan levels occur in the post prandial state, presumably as a result of competition for these receptors [27] . Their relationship to the total matrix content of the liver and to the activity of fibrogenesis or degradation is usually mixed.Indeed, in the absence of a golden standard of matrix turnover, it is not possible to assess the relationship of the levels of these markers to ongoing matrix remodeling and new matrix deposition or removal.Thus from a practical and research standpoint, it would be ideal to have marker(s)that can: (a) Noninvasively stage the degree of liver fibrosis; or (b) Reflect the rate of matrix deposition or removal, both to monitor the impact of therapies and to give prognostic information.It is unlikely that any single marker can fulfill both of these ideal criteria These markers are supposed to be directly involved in the deposition and removal of ECM, i.e.in fibrogenesis and fibrolysis.They include markers of matrix metabolism as well as cytokines.Fibrosis markers can be classified according to their molecular structure (Table 2) . 
4) Laminin
A major non-collagenous glycoprotein synthetized by HSC, laminin is deposited in the basement membrane of the liver and increases during fibrosis around the vessels, in the perisinusoidal spaces and the portal tract.Serum laminin levels and pepsin-resistant fragment of laminin (laminin P1)are elevated in chronic liver diseases irrespective of etiology: viral or alcoholic and reflect an increase in perisinusoidal fibrosis.Serum levels of laminin correlate with the severity of fibrosis and liver inflammation in chronic hepatitis C, and are superior to serum ALT in reflecting liver injury [31].
5)
Hyaluronic acid Hyaluronic acid (HA)is a glycosaminoglycan, component of the ECM, synthetized by HSC.In normal circumstances the endothelial cells of the liver sinusoid are the site of HA uptake and degradation [32] . Increased levels of HA are due to decreased hepatic removal, increased production or both.High levels of serum HA were detected in patients with liver diseases of different etiologies and particularly in those with cirrhosis [33] .Serum levels of HA were shown to be related not only to the stage of fibrosis but also to the degree of necroinflammation [30] .
6)
YKL-40 (chondrex) YKL-40 is a mammalian member of a chitinase family ( 18-glycosylhydrolases).YKL-40 is produced in a wide variety of cell types and especially in cells located in tissues with increased remodelling/ degradation or inflammation of the ECM.The cellular source in the liver is supposed to be activated HSC.Its physiological function is unknown, but YKL-40 may contribute to tissue remodelling, acts as a growth factor for fibroblasts, acts synergistically with insulin-like growth factor, as a chemoatractant for endothelial cells and has a role in angiogenesis.In liver diseases, serum levels of YKL-40 were closely related to the degree of fibrosis histologically documented, the highest values being found in severe fibrosis [34] . In chronic HCV infection, serum levels greater than 284.8 ng/ml predict cirrhosis with a sensitivity of 80 %and specificity of 71% and have a negative predictive value (NPV)of 78%.Unlike PIIINP and HA, serum YKL -40 is significantly elevated in the subset of alcoholic cirrhotic patients who have also alcoholic hepatitis and is the best of these serological markers in discriminating between patients with mild fibrosis and those with no fibrosis Older studies which investigated the role of TIMP-1 in patients with various liver disease, comparing TIMP-1 with PIIINP, type IV collagen, laminin P 1 and the histological aspect, suggested that the serum levels of TIMP1 may be useful to estimate hepatic fibrogenesis associated with active inflammatory activity. Also, the serum levels of TIMP-1 were shown to correlate positively with the degree of fibrosis and a striking increase in serum TIMP-1 levels was observed in the late stage of fibrosis, but not in the mild stage the ratio of TMP -1/MMP-1 could be useful in the diagnosis of hepatic fibrosis [38]. CCytokines and chemokines associated with hepatic fibrosis 1-TGF -β 1 Transforming growth factor-β1(TGF -β 1)is a homodimetric polypeptide that is secreted in an inactive form which requires activation. It has pleiotropic effects through membrane receptors on a wide variety of cells .In hepatic pathology, TGF -β 1 is the most important stimulus for the production of ECM by HSC and it is also an inhibitor of hepatocyte growth and proliferation [39].In the liver biopsy from patients with chronic liver disease, TGF -β 1 , mRNA levels correlate with type I collagen mRNA (40]. The value of serum TGF -b1 levels has some limitations related to the contamination of the sample by TGF -β from platelets, the interference with plasmin activity in the plasma that increases the amount of TGF -β 1 through opening LAPTGF -β complex, the binding of TGF -β at the sites of injury to ECM and to vascular endothelium, the sequestration by soluble proteins and the complicated clearance of TGF -β 1.These factors explain why plasma levels of TGF β1 are unlikely to be of diagnostic value [40]However, some authors showed a good correlation between serum levels of total TGF -β , and Knodell scores and also a correlation with the rate of fibrosis progression [ the correlation of individual direct markers with fibrosis and inflammation is shown in (Table 14) . 
9-Forns index Forns et al.(2002)
reported an index based on four readily available variables; age, platelet count, γ glutamyltransferase, and cholesterol levels.The study was confined to patients with hepatitis C and included both test and validation cohorts.The authors constructed a simple score system applying a constant to the obtained formula Based on their analysis of these laboratory tests, they found that the APRI was the simplest and the most accurate test for the evaluation of two end points. It is calculated as follows:APRI = AST level / ULN x 100 Platelet count (10 9 /l) Platelet counts and AST levels were found to be the most important predictors of significant fibrosis and cirrhosis.This novel index was developed to amplify the opposing effects of fibrosis on AST and platelet count.By using the optimized cut off values, significant fibrosis could be predicted accurately in 51 % and cirrhosis in 81 % of patients [60] 11-Göteborg University Cirrhosis Index (GUCI) In this study, samples from 179 patients with chronic hepatitis C were analyzed using routinely available biochemical markers of liver disease, and compared with liver biopsy using the Ishak protocol. Multivariate logistic regression analysis revealed strong association between AST, platelet count and prothrombin -INR.They developed the G ö teborg University Cirrhosis Index (GUCI)according to the formula: Using a cut-off value of 1.0, the sensitivity was 80 %, and the specificity 78% for the diagnosis of cirrhosis, and the negative predictive value and the positive predictive values were 97 % and 31 % respectively.The authors concluded that the GUCI score proved slightly superior for sensitivity, specificity, NPV, PPV, and the area under the receiver operating characteristic curve (ROC)for the prediction of cirrhosis and bridging fibrosis compared with AST to platelet ratio index (APRI) [61] . 
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